What advantages do bacterial vectors offer for vaccine delivery?

Bacterial vectors can induce strong mucosal immunity, act as inherent adjuvants, and allow for convenient administration routes, such as oral delivery.

Can bacterial vector vaccines target multiple diseases or antigens?

Yes, they can be designed to deliver multiple antigens, enabling multivalent vaccines that provide broad-spectrum protection against various strains or pathogens.

What types of bacteria does Creative Biolabs use as vectors?

Creative Biolabs utilizes various attenuated bacterial strains, including Salmonella, Listeria, Mycobacterium bovis BCG, and beneficial probiotics, as vaccine delivery platforms.

What kind of customization does Creative Biolabs offer for bacterial vector vaccine design?

Creative Biolabs provides highly customized design, tailoring vaccine candidates to specific pathogens and their virulence factors, and optimizing antigen expression and delivery.

What preclinical services does Creative Biolabs offer for bacterial vector vaccines?

Creative Biolabs supports the entire preclinical pipeline, from initial design and engineering to comprehensive immunogenicity and efficacy evaluations in relevant models.

What key technologies does Creative Biolabs integrate into its bacterial vector vaccine services?

We integrate advanced technologies such as bacterial surface display, secretion systems, and balanced lethal vector systems for efficient and precise antigen delivery.

Virus-Like Particle based Vaccine Solution

Creative Biolabs offers comprehensive preclinical services for Virus-Like Particle (VLP) based vaccine development. We provide end-to-end support, from initial VLP design and engineering to robust manufacturing utilizing diverse expression systems including bacteria, yeast, insect, and mammalian cells. Our expertise includes developing non-infectious VLP candidates that effectively mimic viral structures to elicit strong, targeted immune responses. We also specialize in chimeric VLP designs, delivering advanced solutions for broad-spectrum protection in early-stage vaccine research.

Talk To Our Vaccine Experts View Services Available products

End-to-end virus-like particle based vaccine solutions

What is a Virus-Like Particle based vaccine?

Virus-Like Particles (VLPs) are innovative vaccine platforms that mimic the structure of authentic viruses but lack viral genetic material, making them non-infectious and inherently safe. These nanometer-sized particles are composed of viral structural proteins that self-assemble into highly immunogenic structures resembling native virions. VLP vaccines effectively stimulate both humoral and cellular immune responses by presenting viral antigens in their natural conformation. Their repetitive surface geometry triggers strong B-cell activation, while their particulate nature facilitates efficient uptake by antigen-presenting cells.

Comprehensive Virus-Like Particle based Vaccine Preclinical Solution

Creative Biolabs specializes in designing VLP vaccines using various expression systems (mammalian, insect, bacterial, yeast) for diverse pathogens. This technology combines the immunogenicity advantages of whole-virus vaccines with superior safety profiles, making VLPs ideal candidates for vaccines against challenging diseases like HPV, hepatitis B, and emerging viral threats. The platform also enables multivalent vaccine development by incorporating antigens from multiple strains or pathogens into a single VLP structure.

Comprehensive Service Portfolio

Vaccine Design Adjuvant selection Analysis & ValidationFormulation Development Preclinical Testing

Customized Virus-Like Particle based Vaccine Design

Structural Design Engineering: Precision engineering of VLP scaffolds (e.g., icosahedral/enveloped) with customized antigen presentation patterns for optimal immune recognition.
Epitope-Focused Design: Computational design of conformationally-correct epitopes displayed on VLPs to elicit targeted neutralizing antibody responses.
Chimeric VLP Platforms: Development of hybrid VLP systems combining structural components from multiple viruses for enhanced stability and immunogenicity.
Modular Antigen Docking: Implementation of plug-and-display systems (e.g., SpyTag/SpyCatcher) for rapid antigen exchange on standardized VLP carriers.

Adjuvant Development & Optimization

Adjuvant Screening & Formulation: High-throughput evaluation of immune-boosting adjuvants (TLR agonists, cytokines) for optimal VLP-adjuvant synergy and enhanced immunogenicity.
Structural Integration: Genetic fusion or chemical conjugation of adjuvants (e.g., flagellin, CpG) directly onto VLPs to ensure co-delivery and targeted immune activation.
Mucosal Adjuvant Design: Development of specialized adjuvants (M-cell ligands, chitosan) for oral/nasal VLP vaccines to enhance mucosal immunity.

Analytical Development & Preclinical Validation

Comprehensive VLP Characterization: Advanced analytical methods (HPLC, SDS-PAGE, NTA, TEM) for purity, size distribution, and structural integrity assessment of VLPs to ensure quality and consistency.
Immunogenicity Profiling: In-depth evaluation of humoral (ELISA, neutralizing antibodies) and cellular (ELISpot, flow cytometry) immune responses in preclinical models to confirm vaccine efficacy.
Safety & Toxicology Studies: GLP-compliant in vivo assessments (acute/chronic toxicity, biodistribution) in rodent and non-rodent models to validate VLP vaccine safety profiles.

Formulation & Process Development

Optimized VLP Formulation: Tailored lyophilization and adjuvant (e.g., AddaVax, CpG) formulations to enhance VLP stability and immunogenicity, ensuring long-term storage viability and robust immune responses.
Mucosal Vaccine Formulation: Specialized enteric coatings and nanoparticle encapsulation for oral/nasal VLP delivery, enhancing mucosal immunity.
Process Analytical Technology (PAT): Real-time monitoring of critical quality attributes (CQAs) during fermentation and purification to ensure batch consistency.

Preclinical Testing

Challenge & Protection Studies: Controlled pathogen exposure models to assess vaccine-induced protection against target infections (e.g., influenza, RSV).
Mucosal Immune Response Analysis: Specialized assays for nasal/oral VLP vaccines, measuring IgA, T-cell homing, and mucosal barrier protection.

Featured Virus-Like Particle based Vaccine Design Services

Fluorescent Virus-Like Particle Design

Facilitation of dynamic tracking of VLP behavior in vitro and in vivo, aiding in vaccine mechanism studies.
Maintenance of VLP structural integrity and antigenicity despite fluorescent label incorporation.
Enabling precise analysis of VLP uptake, processing, and presentation by immune cells.

Chimeric VLP based Vaccine Design

Induction of cross-reactive immune responses against diverse viral strains or related pathogens.
Optimization of antigen spacing and presentation to enhance immune recognition and response potency.
Reduction of vaccination regimens by targeting multiple pathogens in a single vaccine formulation.

Enveloped Virus-Like Particle based Vaccine Design

Preservation of conformational epitopes critical for neutralizing antibody induction, mimicking natural viral infection.
Stimulation of both humoral and cellular immunity through envelope-mediated interactions with immune cells.
Effective targeting of enveloped viruses, including those with complex surface antigen architectures.

How Dose Virus-Like Particle based Vaccine Solution Work?

1. Antigen Design and Optimization

Pathogen genome analysis based on high-throughput sequencing platform
AI online platform predicts highly immunogenic epitopes
Optimizing and modifying candidate antigens to enhance their immunogenicity and stability.

2. Immunization Strategy Development

Outer Membrane Vesicle Platform induces antigen expression
Optimization of adjuvant compatibility (aluminum adjuvant, TLR agonist)
Delivery system customization (nanoparticles/liposomes)

3. Immunogenicity Assessment

Humoral immunity testing (IgG/IgA subtypes, neutralizing antibody titers)
Cellular immune assay (Th1/Th2/Th17 response profile)
ADCP/ADCD functional verification

4. Animal Model Verification

Customized challenge model (mouse/guinea pig/rabbit)
Protection effectiveness evaluation (LD50, Totally Synthetic load monitoring)
Safety assessment (local/systemic toxicity)

5. Report

Screening analysis reports
Test data reports
Project design document

Online Inquiry

Getting Started with Your Vaccine Project

Professional Vaccine Solution platform

Antigen Prediction System Platform

Our Antigen Prediction System Platform integrates advanced bioinformatics and computational biology tools to identify and prioritize immunogenic antigens. Leveraging cutting-edge algorithms, we analyze pathogen genomes or cancer markers to predict key epitopes that elicit robust immune responses. This platform enables the rational design of vaccines by pinpointing high-potency antigens, significantly accelerating the development process for bacterial, viral, fungal, parasitic, and cancer-targeted vaccines. By combining traditional immunology with state-of-the-art predictive modeling, we ensure optimal antigen selection for maximum immunogenicity and efficacy.

Protein Expression Platform

The Protein Expression Platform at Creative Biolabs offers versatile solutions for producing recombinant antigens using multiple expression systems. We specialize in optimizing bacterial (e.g., E. coli), yeast, insect, and mammalian cell systems to meet diverse production needs. Our expertise in genetic engineering allows us to tailor expression vectors, culture conditions, and purification protocols for high-yield, biologically active proteins. Whether for preclinical research or large-scale manufacturing, our platform ensures consistent production of immunogenic proteins, supporting the development of vaccines with enhanced stability and immunogenicity. We seamlessly integrate expression technologies with downstream analytical and formulation services to streamline the vaccine development pipeline.

Modular Delivery System Platform

Our Modular Delivery System Platform is designed to enhance vaccine potency and delivery efficiency through customizable, multi-component formulations. Focused on optimizing delivery mechanisms, we develop lipid-based nanoparticles, viral-like particles (VLPs), and other nano-carriers to protect antigens, improve cellular uptake, and modulate immune responses. The modular design allows for precise integration of adjuvants, targeting ligands, and protective matrices, enabling tailor-made systems for various vaccine types—from prophylactic to therapeutic.

Why Choose Our Virus-Like Particle based Vaccine Services?

High Immunogenicity

VLPs mimic viruses, triggering strong and broad immune responses for better protection.

Fast & Scalable Production

Modular design enables rapid antigen updates and large-scale manufacturing.

Safe & Clinically Proven

Non-infectious VLPs with high purity (>90%) and validated efficacy.

Flexible Delivery Options

Supports multiple routes (IM, nasal) and customizable adjuvants for enhanced immunity.

Available Products

Antigen Products Antibody Products Adjuvant Products Delivery System related Products

Array Kits Cell Culture Medium Proudcts

FAQs About Our Virus-Like Particle based Vaccine Solution

What advantages do bacterial vectors offer for vaccine delivery?

Bacterial vectors can induce strong mucosal immunity, act as inherent adjuvants, and allow for convenient administration routes, such as oral delivery.
Can bacterial vector vaccines target multiple diseases or antigens?

Yes, they can be designed to deliver multiple antigens, enabling multivalent vaccines that provide broad-spectrum protection against various strains or pathogens.
What types of bacteria does Creative Biolabs use as vectors?

Creative Biolabs utilizes various attenuated bacterial strains, including Salmonella, Listeria, Mycobacterium bovis BCG, and beneficial probiotics, as vaccine delivery platforms.
What kind of customization does Creative Biolabs offer for bacterial vector vaccine design?

Creative Biolabs provides highly customized design, tailoring vaccine candidates to specific pathogens and their virulence factors, and optimizing antigen expression and delivery.
What preclinical services does Creative Biolabs offer for bacterial vector vaccines?

Creative Biolabs supports the entire preclinical pipeline, from initial design and engineering to comprehensive immunogenicity and efficacy evaluations in relevant models.
What key technologies does Creative Biolabs integrate into its bacterial vector vaccine services?

We integrate advanced technologies such as bacterial surface display, secretion systems, and balanced lethal vector systems for efficient and precise antigen delivery.

Related Resources

Download Resources

Literature Center

Podcast